Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Samuraciclib + Vepdegestrant |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Samuraciclib | CT 7001|CT7001|CT-7001|ICEC0942 | CDK7 Inhibitor 16 | Samuraciclib (ICEC0942) is an orally available and selective CDK7 inhibitor that prevents Cdk7 phosphorylation to induce cell cycle arrest and apoptosis (PMID: 29545334, PMID: 32150405). | |
Vepdegestrant | ARV471|ARV 471|PF 07850327|PF07850327|PF-07850327|ARV-471 | Hormone - Anti-estrogens 29 | Vepdegestrant (ARV-471) is a bifunctional molecule that targets the estrogen receptor (ESR1), including ESR1 variants, for proteolytic degradation resulting in reduced target gene expression and potentially leading to reduced cell proliferation and inhibition of tumor growth (Cancer Res 2019;79(4 Suppl):Abstract nr P5-04-18, PMID: 32829249). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06125522 | Phase II | Samuraciclib + Vepdegestrant | TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C) | Recruiting | USA | ITA | FRA | ESP | CAN | BEL | 1 |